This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe purpose of this study is to compare the assessments of orphan and non-orphan drugs by NICE.
Read morePatents are usually only valid for around 20 years however, as patenting occurs early in the R&D pro...
Read moreWith many anticipated new medicines for rare diseases, countries are beginning to prepare appropriat...
Read moreThe HST process is a method for evaluating medicines and treatments specifically indicated for ultra...
Read moreNICE’s Highly-Specialised Technologies (HST) process is a method for evaluating medicines and trea...
Read moreLast month, EMA published its overview of key recommendations for 2020 on the authorisation and safe...
Read moreDifferences in market access and reimbursement processes are an important factor in determining the ...
Read moreOrphan drugs have important societal value as they improve patient quality of life and address unmet...
Read more